Left ventricular diastolic function with epirubicin therapy: an echodoppler study.

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Epirubicin is a common chemotherapy agent for lung cancer.
• Cardiotoxicity is a known side effect of anthracycline chemotherapy.
• Assessing early cardiac function changes is crucial for patient management.

Purpose of the Study:

• To evaluate the impact of epirubicin therapy on left ventricular function and filling dynamics in lung cancer patients.
• To identify potential subclinical cardiac changes induced by epirubicin.

Main Methods:

• Echocardiography and Doppler echocardiography were used to assess cardiac parameters.
• Key measurements included 2D ejection fraction (EF) and Doppler left ventricular filling parameters (peak E, peak A, E/A ratio).
• Measurements were taken before and after epirubicin therapy completion in 30 primary lung cancer patients.

Main Results:

• No significant differences were observed in mean ejection fraction or Doppler filling parameters.
• However, 20% of patients (6 out of 30) exhibited left ventricular filling abnormalities.
• Two patients also showed a slight reduction in ejection fraction, with abnormalities appearing dose-related.

Conclusions:

• Epirubicin therapy may induce subclinical left ventricular filling abnormalities in a subset of lung cancer patients.
• These cardiac changes appear to be dose-dependent.
• Further long-term studies are needed to determine reversibility and clinical significance.